A Study of HS269 in Patients With Advanced Solid Tumors

Phase 1

• Conditions: Advanced Solid Tumor
• Interventions: Drug: HS269

• Registration Number: NCT05058352
• Lead Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.

Brief Summary

This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-02
• Study First Submitted QC: 2021-09-24
• Last Update Submitted: 2021-09-24
• Study First Posted: 2021-09-27
• Last Update Posted: 2021-09-27
• Study Start: 2021-10
• Primary Completion: 2022-10
• Study Completion: 2023-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. ≥18 years, no gender limit.

2. Patients with advanced solid tumors confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment, or standard treatment is not applicable at this stage.

3. At least one evaluable tumor lesion according to RECIST version 1.1.

4. ECOG≤ 1.

5. The estimated survival time was more than 3 months.

6. The function of all organs was good, the specific indexes were as follows:

   Blood system (no transfusion or hematopoietic stimulating factor treatment within 14 days) i. #NEUT ≥1.5×109/L ii. PLT ≥90×109/L iii. HGB ≥85g/L Liver function i. TBIL ≤1.5×ULN ii. ALT ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN iii. AST ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN Renal function i. Ccr >50 ml/min（According to Cockcroft-Gault formula） Blood coagulation function i. APTT ≤1.5×ULN ii. INR ≤1.5×ULN

7. The subjects should be informed and agreed to the study before the start of the trial, and sign the written informed consent voluntarily.

Exclusion Criteria

1. Received anti-tumor treatments within 14 days or less than 5 half-lives (whichever is longer) before the first use of the study drug

2. Received blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor and other treatments within 7 days before receiving blood system examination during the screening period.

3. Received other unmarketed clinical study drugs or treatments within 4 weeks before the first use of the study drug.

4. Major organ surgery (excluding biopsy) or significant trauma occurred within 4 weeks before the first use of the study drug;

5. Systemic administration of glucocorticoids (prednisone > 10 mg / day or equivalent dose of the same drug) or other immunosuppressants within 14 days before the first use of the study drug; except for local, eye, intra articular, nasal and inhaled corticosteroids; short-term use of glucocorticoids for preventive treatment (e.g. prevention of contrast agent allergy)；

6. CYP1A2/P-gp potent inhibitors or potent inducers were used within 7 days before the first use of the study drug；

7. Resistance to selective RET inhibitors;

8. The adverse reactions of previous anti-tumor therapy have not yet recovered to CTCAE 5.0 grade evaluation ≤ 1 (except for the toxicity without safety risk judged by researchers such as alopecia)；

9. Patients with central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that the central nervous system metastasis or meningeal metastasis has not been controlled, which is not suitable for the study.

10. Have active infection and need systemic anti infection therapy；

11. Have a history of immunodeficiency, including HIV antibody test positive；

12. Active hepatitis B, allowing preventive antiviral treatment other than interferon; hepatitis C virus infection；

13. Present or past interstitial lung disease (except radiation-induced pulmonary fibrosis without hormone therapy)；

14. Poorly controlled diabetic patients.

15. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to:

    1. Serious abnormal cardiac rhythm or conduction, such as ventricular arrhythmia, Ⅱ - Ⅲ degree atrioventricular block, etc;
    2. In the resting state, average QTcF≥480ms in 12 lead -ECG；
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular events of grade 3 or above occurred within 6 months before the first administration;
    4. NYHA ≥II or LVEF<50％；
    5. Hypertension beyond clinical control；

16. Could not take medication orally，or have severe gastrointestinal obstruction (such as gastrointestinal obstruction, gastrointestinal absorption)；

17. The third space effusion, which could not be controlled clinically, was not suitable for the study；

18. Mental disorder or poor compliance；

19. Eligible patients with fertility (male and female) do not agree to use reliable contraceptive methods (abstinence, condom, intrauterine device or ligation) with their partner during the trial and for at least 3 months after the last medication.

20. Female patients have a positive blood pregnancy test within 7 days before enrollment, or breastfeeding women;

21. The subjects were not suitable for the clinical study because of other serious systemic diseases or other reasons according to the investigator 's judgment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
HS269	HS269	Multiple doses of HS269 tablets

Primary Outcome Measures

Name	Time	Method
Dose limiting toxicities (DLT)	From date of initial dose until up to 33 days for treatment	Incidence rate of dose limiting toxicities (DLT)
Adverse Event(s) and Serious Adverse Event(s)	Through study completion or early study discontinuation（up to 12 months）	The occurrence and rate of AE and SAE

Secondary Outcome Measures

Name	Time	Method
ORR	Approximately 12 months	Objective response rate (ORR)
DCR	Approximately 12 months	Disease control rate (DCR)
PFS	Approximately 12 months	Progression free survival (PFS)
Peak Plasma Concentration (Cmax)	From date of initial dose until up to 33 days for treatment	Cmax of HS269
Area Under the Plasma Concentration versus Time Curve (AUC)	From date of initial dose until up to 33 days for treatment	AUC of HS269
Calcitonin in Peripheral Blood	Through study completion or early study discontinuation（up to 12 months）	For Medullary Thyroid Cancer patients
Thyroglobulin in Peripheral Blood	Through study completion or early study discontinuation（up to 12 months）	For non-MTC thyroid cancer patients
Peripheral blood ctDNA	Through study completion or early study discontinuation（up to 12 months）	Only for patients with positive RET gene mutation

Trial Locations

Locations (1)

Shanghai Pulmonary Hospital; 🇨🇳 Shanghai, China